NCT07281170

Brief Summary

Objective: 1. To systematically screen the high-risk population of diabetes in Xinqiao area, understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in the high-risk population and patients with prediabetes, and establish the first standardized research cohort of high-risk patients and prediabetes patients in Songjiang area. 2\. Use CGM monitoring technology to identify the high-risk groups of diabetes and the fluctuation of blood glucose in pre-diabetes, understand their ophthalmology and bone density, observe the annual conversion rate of diabetes, find effective interventions, move forward the management of diabetes, and create a new model for the management of high-risk groups of diabetes. Research content: Part I: Establishing the first standardized diabetes high-risk population research cohort in Songjiang area The initiative focuses on early screening for high-risk populations with diabetes, shifting the focus downward and advancing prevention measures to detect diabetes at an earlier stage and initiate timely intervention. In Xinqiao District, all high-risk screening cases will undergo medical history documentation, anthropometric measurements, laboratory testing, and regular follow-ups. Standard oral glucose tolerance test (OGTT) methods will be employed to assess fasting blood glucose levels, insulin sensitivity, 2-hour postprandial glucose and insulin levels after a 75g glucose load, and glycated hemoglobin levels. Beyond evaluating glucose metabolism, the screening will also detect other metabolic disorders through routine blood tests including urinalysis, liver/kidney function tests, uric acid levels, lipid profiles, thyroid function, and urine protein/creatinine ratio. The establishment of this premium high-risk screening program in Xinqiao Community will create Songjiang District's first standardized research cohort for diabetes mellitus (DM) and prediabetes patients, carrying significant strategic importance. Part II: By integrating Clinical Monitoring (CGM) technology with ophthalmological evaluations and bone density ultrasound examinations, we identify characteristics of high-risk diabetic populations and track their disease progression. The CGM system (with auxiliary devices such as the Shansheng Dynamic Glucose Monitoring System) is utilized to monitor blood glucose fluctuations in these individuals. Concurrently, comprehensive ophthalmic assessments-including visual acuity tests, intraocular pressure measurements, fundus photography, OCT scans, OCTA imaging, and SLO examinations-are conducted alongside bone density testing. Annual follow-up evaluations are performed to track clinical outcomes. Research innovation points and expected results: Research innovation points: Establish the first standardized research cohort of high-risk and pre-diabetic patients in Songjiang area; move forward the management of diabetes, and create a new management model for high-risk groups of diabetes. anticipated results

  1. 1.Establish a new standardized diabetes high-risk population research cohort with large sample size.
  2. 2.Observe the metabolic characteristics, blood glucose fluctuation, ophthalmic conditions and bone density of high-risk groups with diabetes.
  3. 3.Find effective interventions to reduce the annual conversion rate of diabetes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7,000

participants targeted

Target at P75+ for all trials

Timeline
105mo left

Started Oct 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Oct 2019Dec 2034

Study Start

First participant enrolled

October 8, 2019

Completed
5.9 years until next milestone

First Submitted

Initial submission to the registry

September 17, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 15, 2025

Completed
8.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 20, 2034

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2034

Last Updated

December 15, 2025

Status Verified

December 1, 2025

Enrollment Period

15 years

First QC Date

September 17, 2025

Last Update Submit

December 1, 2025

Conditions

Keywords

xinqiaoPre DiabeticNICE

Outcome Measures

Primary Outcomes (1)

  • The prevalence of diabetes in high-risk groups during the study

    through study completion, an average of 5 year

Secondary Outcomes (1)

  • FPG HbA1c and TIR changes from baseline in high-risk groups

    through study completion, an average of 5 year

Study Arms (1)

High-risk population for diabetes

Eligibility Criteria

Age20 Months - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Residents of the high-risk diabetes population who have been living in the Xinqiao community for a long time

You may qualify if:

  • Individuals who provide written informed consen
  • Have access to a smartphone
  • Hamily history of diabetes or abnormal microglucose level detected once
  • Age ≥18 years at the time of consent

You may not qualify if:

  • Diabetes mellitus
  • Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study
  • recently surgical histories, trauma, acute cardiovascular complications, or infectious diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, 200000, China

RECRUITING

MeSH Terms

Conditions

Glucose Intolerance

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of endocrinology and metabolism department

Study Record Dates

First Submitted

September 17, 2025

First Posted

December 15, 2025

Study Start

October 8, 2019

Primary Completion (Estimated)

October 20, 2034

Study Completion (Estimated)

December 31, 2034

Last Updated

December 15, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations